^
Association details:
| Biomarker: | RBMS3 deletion |
|---|---|
| Cancer: | Ovarian Cancer |
| Drug: | foscenvivint (PRI724) (CBP inhibitor, β-catenin inhibitor, Wnt signalling pathway inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Loss of RBMS3 Confers Platinum Resistance in Epithelial Ovarian Cancer via Activation of miR-126-5p/ß-catenin/CBP signaling
Excerpt:
Importantly, ICG-001 treatment of RBMS3-deleted/silenced cells significantly enhanced the inhibitory effects of CDDP on clonogenic growth and CDDP-induced apoptosis compared with RBMS3-nondeleted cells (Supplementary Fig. S7G and S7H). The superiority of the combination effects was further confirmed by the drug combination index, which indicated a synergistic effect of ICG-001 and CDDP in RBMS3-deleted cells, but not in RBMS3-nondeleted cells (Supplementary Fig. S7I).
DOI:
10.1158/1078-0432.CCR-18-2554
